Sample Sizes for Designing Bioequivalence Studies for Highly Variable Drugs
Purpose. To provide tables of sample sizes which are required, by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), for the design of bioequivalence (BE) studies involving highly variable drugs. To elucidate the complicated features of the relationship between sam...
Main Authors: | Laszlo Endrenyi, Laszlo Tothfalusi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2011-12-01
|
Series: | Journal of Pharmacy & Pharmaceutical Sciences |
Online Access: | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/11612 |
Similar Items
-
Regulatory and Study Conditions for the Determination of Bioequivalence of Highly Variable Drugs
by: Laszlo Endrenyi, et al.
Published: (2009-05-01) -
Determination of Bioequivalence for Drugs with Narrow Therapeutic Index: Reduction of the Regulatory Burden
by: Laszlo Endrenyi, et al.
Published: (2013-11-01) -
Do Regulatory Bioequivalence Requirements Adequately Reflect the Therapeutic Equivalence of Modified-Release Drug Products?
by: Laszlo Endrenyi, et al.
Published: (2010-05-01) -
Model-Based Approach for Designing an Efficient Bioequivalence Study for Highly Variable Drugs
by: Eunjung Song, et al.
Published: (2021-10-01) -
Highly variable medicines - specific aspects of bioequivalence studies
by: D. P. Romodanovsky, et al.
Published: (2018-02-01)